XTNT logo

XTANT MEDICAL HOLDINGS INC

XTNTNYSE AMERICAN
πŸ† #3214 by market capEarnings Nov 6US Equity
$0.32β–Ό $0.09 (βˆ’28.25%)
Live
1hβ€”
24hβ–Ό 28.3%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$45M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-0.3%
Declining
πŸ“ŠGross Margin
62.3%
High
πŸ’΅FCF Margin
8.3%
Moderate
βš–οΈP/S Ratio
0.5x
Cheap
Otter Score
48
Weak
No chart data available for XTNT.

Trading Snapshot

Day Range
$0.32 – $0.32
52-Week Range
$0.39 – $0.95
Volume
$3.36B
Avg Volume
$2.64B
Shares Outstanding
140.3M
Next Earnings
Oct 17, 2026

Fundamentals Snapshot

Annual Revenue
$134M
Last Q Revenue
$23M
P/E Ratio
34.1
P/S Ratio
0.5x
EPS (TTM)
$0.01
Dividend Yield
β€”

Why Investors Own XTNT

  • βœ“High-growth profile β€” revenue up +38.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 26% gross margin and 4% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$134Mβ–² +41.8% YoY
Gross Margin (TTM)
26.0%β–² +1.6% YoY
Operating Income (TTM)
$17Mβ–² +41.8% YoY
Free Cash Flow (TTM)
$5Mβ–² +41.8% YoY

About XTANT MEDICAL HOLDINGS INC

Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
48/100

Analyst Price Target

β“˜
Average Target
$0.42
β–² +31.3% Upside
High Target$0.51
Low Target$0.36
Based on 36 analysts

Latest News & Updates